Recce Pharmaceuticals (RCE) AGM 2025 Presentation summary

Opening remarks and agenda

• Presented an overview of the company's mission to address antibiotic resistance with novel synthetic anti-infectives and outlined the agenda focused on clinical progress, financials, and strategic initiatives.

Financial performance review

• Market capitalisation as of October 2025 was AUD $121.46 million, with a share price of AUD $0.405 and 289.18 million shares on issue.

• Secured non-dilutive financing via a debt facility of up to AUD $30 million with Avenue Capital Group.

• Received AUD $54.95 million in Advanced Overseas Finding from the Australian Government, extending R&D rebates globally for three years.

• Canadian government rebate of US $175,122 received for scientific research and experimental development.

Board and executive committee updates

• Board chaired by Dr John Prendergast, with extensive experience in pharmaceutical asset commercialisation and capital raising.

• CEO James Graham highlighted for his expertise in global business development and capital raising.

• Dr Alan Dunton, Chief Medical Advisor, brings over 30 years of drug development experience, including multiple new drug approvals.

• Michele Dilizia, Executive Director & CSO, co-led R&D and global patent portfolio development.

• Dr Justin Ward, Executive Director & Principal Quality Chemist, focuses on regulatory compliance and manufacturing standards.